Checkpoint Therapeutics, Inc. | Business Contracts

Securities Purchase Agreement, dated as of February 20, 2023, by and between Checkpoint Therapeutics, Inc. and the Purchaser (Filed With SEC on February 22, 2023)

Amendment to Checkpoint Therapeutics, Inc. Amended and Restated 2015 Incentive Plan (Filed With SEC on December 5, 2022)

Description of Securities of Checkpoint Therapeutics, Inc (Filed With SEC on March 28, 2022)

Master Services Agreement between Samsung Biologics Co., Ltd. and Checkpoint Therapeutics, Inc., effective November 8, 2017 (Filed With SEC on November 6, 2020)

Form of Placement Agent Warrant (Filed With SEC on February 22, 2023)

Form of Series A/B Common Stock Purchase Warrant (Filed With SEC on February 22, 2023)

Form of Pre-Funded Common Stock Purchase Warrant (Filed With SEC on February 22, 2023)

Securities Purchase Agreement, dated as of December 14, 2022, by and between Checkpoint Therapeutics, Inc. and the Purchaser (Filed With SEC on December 16, 2022)

Form of Placement Agent Warrant (Filed With SEC on December 16, 2022)

Form of Series A/B Common Stock Purchase Warrant (Filed With SEC on December 16, 2022)

Form of Pre-Funded Common Stock Purchase Warrant (Filed With SEC on December 16, 2022)

Description of Securities of Checkpoint Therapeutics, Inc (Filed With SEC on March 12, 2021)

Amendment No. 5, dated September 24, 2020, to the Executive Employment Agreement dated October 13, 2015, by and between Checkpoint Therapeutics, Inc. and James F. Oliviero III (Filed With SEC on November 6, 2020)

Underwriting Agreement, entered into by and between Checkpoint Therapeutics, Inc. and H.C. Wainwright & Co., LLC, on September 17, 2020 (Filed With SEC on September 21, 2020)

Amendment to Checkpoint Therapeutics, Inc. Amended and Restated 2015 Incentive Plan (Filed With SEC on June 4, 2020)

Description of Securities of Checkpoint Therapeutics, Inc (Filed With SEC on March 11, 2020)

Underwriting Agreement, entered into by Checkpoint Therapeutics, Inc. on November 20, 2019, with National Securities Corporation (Filed With SEC on November 20, 2019)

Amendment No. 4, dated October 7, 2019, to the Executive Employment Agreement dated October 13, 2015, by and between Checkpoint Therapeutics, Inc. and James F. Oliviero III (Filed With SEC on November 12, 2019)

Amended and Restated Collaboration Agreement by and between Checkpoint Therapeutics, Inc. and TG Therapeutics, Inc. dated June 19, 2019 (Filed With SEC on August 8, 2019)

Collaboration Agreement by and between Adimab, LLC and Checkpoint Therapeutics, Inc., dated January 22, 2019 (Filed With SEC on March 18, 2019)

Checkpoint Therapeutics, Inc. (20)